Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55437
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 林君榮(Chun-Jung Lin) | |
dc.contributor.author | Ya-Hsuan Lu | en |
dc.contributor.author | 呂亞軒 | zh_TW |
dc.date.accessioned | 2021-06-16T04:02:26Z | - |
dc.date.available | 2018-03-12 | |
dc.date.copyright | 2015-03-12 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-10-16 | |
dc.identifier.citation | Abbott, N.J., Ronnback, L., Hansson, E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci, 7, 41-53.
Amphoux, A., Vialou, V., Drescher, E., Bruss, M., Mannoury La Cour, C., Rochat, C., Millan, M.J., Giros, B., Bonisch, H., Gautron, S. (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology, 50, 941-952. Andre, P., Saubamea, B., Cochois-Guegan, V., Marie-Claire, C., Cattelotte, J., Smirnova, M., Schinkel, A.H., Scherrmann, J.M., Cisternino, S. (2012) Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2. J Cereb Blood Flow Metab, 32, 1989-2000. Antkiewicz-Michaluk, L., Krygowska-Wajs, A., Szczudlik, A., Romańska, I., Vetulani, J. (1997) Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biol Psychiatry, 42, 514-518. Booth, R.G., Castagnoli, N. Jr., Rollema, H. (1989) Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+. Neurosci Lett, 100, 306-312. Bicker, J., Alves, G., Fortuna, A., Falcao, A.(2014) Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review. Eur J Pharm Biopharm, 14, 101-105. Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.P., Fenart, L.(2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov, 6, 650-661. Carina, C. Ferrari., and Rodolfo, Tarelli. (2011) Parkinson's Disease and Systemic Inflammation. Parkinsons Dis. 2011, 436813. Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.P., Fenart, L.(2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov, 6, 650-661. Cui, M., Aras, R., Christian, W. V. et al. (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A, 106, 8043-8048. Coakley, R.J., Taggart, C., McElvaney, N.G., O'Neill, S.J. (2002) Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood, 100, 3383-3391. Chan, G.N., Hoque, M.T., Bendayan, R. (2013) Role of nuclear receptors in the regulation of drug transporters in the brain. Trends Pharmacol Sci, 34, 361-372 Dauer, W., Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron, 39, 889-909. Duan, H. and Wang, J. (2010) Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther, 335, 743-753. Dumont, A.O., Goursaud, S., Desmet, N., Hermans, E. (2014) Differential regulation of glutamate transporter subtypes by pro-inflammatory cytokine TNF-α in cortical astrocytes from a rat model of amyotrophic lateral sclerosis. PLoS One, 16, e97649 DeCuypere, M., Lu, Y., Miller, D.D., LeDoux, M.S. (2008) Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. J Neurochem. 107, 1398-1413. Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., Romero, I.A., Couraud, P.O., Pirmohamed, M. (2012) Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol, 83, 805-814. Friedrich, A., George, R.L., Bridges, C.C., Prasad, P.D., Ganapathy, V. (2001) Transport of choline and its relationship to the expression of the organic cation transporters in a rat brain microvessel endothelial cell line (RBE4). Biochim Biophys Acta, 1512, 299-307. Franzen, B., Duvefelt, K., Jonsson, C., Engelhardt, B., Ottervald, J., Wickman, M., Yang, Y., Schuppe-Koistinen, I. (2003) Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res, 115, 130-146. Fernandez, C., Buyse, M., German-Fattal, M., Gimenez, F. (2004) Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci, 7, 359-371. Gaillard, P.J., van der Sandt, I.C,. Voorwinden, L.H., Vu, D., Nielsen, J.L., de Boer, A.G..(2000) Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res, 17, 1198-1205. Garcia-Esparcia, P., Llorens, F., Carmona, M., Ferrer, I. (2014) Complex Deregulation and Expression of Cytokines and Mediators of the Immune Response in Parkinson's Disease Brain is Region Dependent. Brain Pathol, bpa12137. Geevarghese, A., Herman, I.M. (2014) Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies. Transl Res, 163, 296-306 Guijarro-Munoz, I., Compte, M., Alvarez-Cienfuegos, A., Alvarez-Vallina, L., Sanz, L. (2014) Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J Biol Chem, 289, 2457-2468. Goralski, K.B., Hartmann, G., Piquette-Miller, M., Renton, K.W. (2003) Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol, 139, 35-48. Hayashi, Y., Nomura, M., Yamagishi, S., Harada, S., Yamashita, J., Yamamoto, H. (1997) Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia, 19, 13-26. Hartz, A.M., Bauer, B. (2010) Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Inter, 10, 293-304. Hoban, D.B., Connaughton, E., Connaughton, C., Hogan, G., Thornton, C., Mulcahy, P., Moloney, T.C., Dowd, E. (2013) Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav Immun, 27, 91-100. Itagaki, S., Ganapathy, V., Ho, H.T., Zhou, M., Babu, E., Wang, J. (2012) Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter. Drug Metab Dispos. 40, 1138-1143. Karbach, U., Kricke, J., Meyer-Wentrup, F., Gorboulev, V., Volk, C., Loffing-Cueni, D., Kaissling, B., Bachmann, S., Koepsell, H. (2000) Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol, 279, F679-F687. Kortekaas, R., Leenders, K. L., van Oostrom, J. C., Vaalburg, W., Bart, J., Willemsen, A. T. and Hendrikse, N. H. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol, 57, 176-179. Kotake, Y., Tasaki, Y., Makino, Y., Ohta, S. and Hirobe, M. (1995) 1-Benzyl-1,2,3,4-Tetrahydroisoquinoline as a Parkinsonism-Inducing Agent - a Novel Endogenous Amine in Mouse-Brain and Parkinsonian CSF. J Neurochem, 65, 2633-2638. Koepsell, H., Lips, K., Volk, C. (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res, 24, 1227-1251. Koepsell, H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med, 34, 413-435. Lee, W. K., Reichold, M., Edemir, B., Ciarimboli, G., Warth, R., Koepsell, H. and Thevenod, F. (2009) Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol, 296, F1504-F1513. LeDoux, M. (2004) Tetrahydroisoquinolines and Parkinson's Disease. In: Parkinson's Disease. CRC Press. Lin, C. J., Tai, Y., Huang, M. T., Tsai, Y. F., Hsu, H. J., Tzen, K. Y. and Liou, H. H. (2010) Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem, 114, 717-727. Lips, K.S., Wunsch, J., Zarghooni, S., Bschleipfer, T., Schukowski, K., Weidner, W., Wessler, I., Schwantes, U., Koepsell, H., Kummer, W. (2007) Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol, 51, 1042-1053. Lips, K. S., Luhrmann, A., Tschernig, T. et al. (2007) Down-regulation of the non-neuronal acetylcholine synthesis and release machinery in acute allergic airway inflammation of rat and mouse. Life Sci, 80, 2263-2269. Liou, H.H., Hsu, H.J., Tsai, Y.F., Shih, C.Y., Chang, Y.C., Lin, C.J. (2007) Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. Life Sci, 81, 664-672. Mao, D.Y., Barsyte-Lovejoy, D., Ho, C.S., Watson, J.D., Stojanova, A., Penn, L.Z. (2004) Nucleic Acids Res, 32, 3462-3468. Mei, Q., Richards, K., Strong-Basalyga, K., Fauty, S.E., Taylor, A., Yamazaki, M., Prueksaritanont, T., Lin, J.H., Hochman, J. (2004) J Pharm Sci, 93, 2488-2496. Maruyama, W., Abe, T., Tohgi, H., Dostert, P. and Naoi, M. (1996) A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid. Ann Neurol, 40, 119-122. Matsubara, K., Senda, T., Uezono, T. (1998) Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter. Eur J Pharmacol, 348, 77-84. Mayrand, R. R. and Levitt, D. G. (1983) Urea and ethylene glycol-facilitated transport systems in the human red cell membrane. Saturation, competition, and asymmetry. J Gen Physiol, 81, 221-237. McNaught, K. S., Carrupt, P. A., Altomare, C., Cellamare, S., Carotti, A., Testa, B., Jenner, P. and Marsden, C. D. (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol, 56, 921-933. Meredith, G. E., Sonsalla, P. K. and Chesselet, M. F. (2008) Animal models of Parkinson's disease progression. Acta Neuropathol, 115, 385-398. Mei, Q., Richards, K., Strong-Basalyga, K., Fauty, S.E., Taylor, A., Yamazaki, M., Prueksaritanont, T., Lin, J.H., Hochman, J. (2004) Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2. J Pharm Sci, 93, 2488-2496. Morgan, E.T., Goralski, K.B., Piquette-Miller, M., Renton, K.W., Robertson, G.R., Chaluvadi, M.R., Charles, K.A., Clarke, S.J., Kacevska, M., Liddle, C., Richardson, T.A., Sharma, R., Sinal, C.J. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos, 36, 205-216. Mochizuki, T., Satsu, H., Nakano, T., Shimizu, M. (2004) Regulation of the human taurine transporter by TNF-alpha and an anti-inflammatory function of taurine in human intestinal Caco-2 cells. Biofactors, 21, 141-144. More, S.V., Kumar, H., Kim, I.S., Song, S.Y., Choi, D.K. (2013) Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm, 2013, 952375. Musshoff, F., Schmidt, P., Dettmeyer, R., Priemer, F., Jachau, K., Madea, B. (2000) Determination of dopamine and dopamine-derived (R)-/(S)-salsolinol and norsalsolinol in various human brain areas using solid-phase extraction and gas chromatography/mass spectrometry. Forensic Sci Int, 113, 359-366. Nagatsu, T. (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res, 29, 99-111. Naganuma, F., Yoshikawa, T., Nakamura, T., Iida, T., Harada, R., Mohsen, A.S., Miura, Y., Yanai, K. (2014) Predominant role of plasma membrane monoamine transporters in monoamine transport in 1321N1, a human astrocytoma-derived cell line. J Neurochem, 129, 591-601. Naoi, M., Maruyama, W., Nakao, N., Ibi, T., Sahashi, K., Benedetti, M.S. (1998) (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann Neurol, 43, 212-216. Niwa, T., Takeda, N., Kaneda, N., Hashizume, Y., Nagatsu, T. (1987) Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun, 144, 1084-1089. Nies, A.T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., Zanger, U.M., Keppler, D., Schwab, M., Schaeffeler, E. (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 50, 1227-1240. Ohtsuki, S., Yamaguchi, H., Kang, Y. S., Hori, S. and Terasaki, T. Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. Biol Pharm Bull, 33, 1250-1252. Okura, T., Hattori, A., Takano, Y., Sato, T., Hammarlund-Udenaes, M., Terasaki, T., Deguchi Y. (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos, 36, 2005-2013. Okura, T., Kato, S., Takano, Y., Sato, T., Yamashita, A., Morimoto, R., Ohtsuki, S., Terasaki, T. and Deguchi, Y. (2011) Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers. J Pharm Sci, 100, 3924-3938. Peruzzo, D.C., Benatti, B.B., Andersen, M.L., Tufik, S., Casati, M.Z., Nociti, F.H. (2010) Jr.Cytokine, 52, 184-189. Perry, V.H. (2004) The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun, 18, 407-413. Park, R., Kook, S.Y., Park, J.C., Mook-Jung, I.(2014) Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling. Cell Death Dis, 26, e1299 Pan, W., Yu, C., Hsuchou, H., Kastin, A.J. (2010) The role of cerebral vascular NFkappaB in LPS-induced inflammation: Differential regulation of efflux transporter and transporting cytokine receptors. Cell Physiol Biochem, 25, 623-630. Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., Knapp, D.J., Crews, F.T. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia, 55, 453-462. Rappold, P.M., Cui, M., Chesser, A.S., Tibbett, J., Grima, J.C., Duan, L., Sen, N., Javitch, J.A., Tieu, K. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci U S A, 108, 20766-20771. Shioda, N., Beppu, H., Fukuda, T., Li, E., Kitajima, I., Fukunaga, K. (2011) Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J Neurosci, 31, 346-358. Salkeni, M.A., Lynch, J.L., Otamis-Price, T., Banks, W.A. (2009) Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways. J Neuroimmune Pharmacol, 4, 276-282. Sandler, M., Carter, S. B., Hunter, K. R. and Stern, G. M. (1973) Tetrahydroisoquinoline Alkaloids: in vivo Metabolites of L-Dopa in Man. Nature, 241, 439-443. Seelbach, M.J., Brooks, T.A., Egleton, R.D.,Davis, T.P. (2007) Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: A role for P-glycoprotein. J Neurochem, 102,1677-1690. Storch, A., Hwang, Y. I., Gearhart, D. A., Beach, J. W., Neafsey, E. J., Collins, M. A. and Schwarz, J. (2004) Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake. J Neurochem, 89, 685-694. Storch, A., Ott, S., Hwang, Y. I. et al. (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol, 63, 909-920. Suzuki, K., Kosho, I. and Namiki, H. (2008) Characterization of the unique regulatory mechanisms of phorbol ester-induced polymorphonuclear leukocyte spreading in an acidified environment. Eur J Pharmacol, 588, 301-308. Schapira, A.H., Olanow, C.W., Greenamyre, J.T., Bezard, E. (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, 14, 61010-61012. Shu, Y., Leabman, M.K., Feng, B., Mangravite, L.M., Huang, C.C., Stryke, D., Kawamoto, M., Johns, S.J., DeYoung, J., Carlson, E., Ferrin, T.E., Herskowitz, I., Giacomini, K.M. (2003) Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A, 100, 5902-5907. Sung, J.H., Yu, K.H., Park, J.S., Tsuruo, T., Kim, D.D., Shim, C.K., Chung, S.J. (2005) Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug Metab Dispos, 33, 440-448. Tan, K.H., Purcell, W.M., Heales, S.J., McLeod, J.D., Hurst, R.D. (2002) Evaluation of the role of P-glycoprotein in inflammation induced blood- brain barrier damage. Neuroreport, 13, 2593-2597. Tieu, K. (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med, 1, a009316. Tanga, F.Y., Raghavendra, V., DeLeo, J.A. (2004) Neurochem Int, 45, 397-407. Taubert, D., Grimberg, G., Stenzel, W. and Schomig, E. (2007) Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PloS one, 2, e385. Theron, D., Barraud de Lagerie, S., Tardivel, S., Pelerin, H., Demeuse, P., Mercier, C., Mabondzo, A., Farinotti, R., Lacour, B. (2003) Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line GPNT. Biochem Pharmacol, 66, 579-587. Xia, L., Engel, K., Zhou, M. and Wang, J. (2007) Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol, 292, F682-F690. Yoshikawa, T., Naganuma, F., Iida, T., Nakamura, T., Harada, R., Mohsen, A.S., Kasajima, A., Sasano, H., Yanai, K. (2013) Molecular mechanism of histamine clearance by primary human astrocytes. Glia, 61, 905-916. Young, J.D., Yao, S.Y., Baldwin, J.M., Cass, C.E., Baldwin, S.A. (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med, 34, 529-547. Yamakawa, T., Kotake, Y., Fujitani, M., Shintani, H., Makino, Y., Ohta, S. (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett, 276, 68-70. Yu, C., Argyropoulos, G., Zhang, Y., Kastin, A.J., Hsuchou, H., Pan, W. (2008) Neuroinflammation activates Mdr1b efflux transport through NFkappaB: Promoter analysis in BBB endothelia. Cell Physiol Biochem, 22, 745-756. Zorzi, P., Aplin, A.C., Smith, K.D., Nicosia, R.F. (2010) J Leukoc Biol, 88, 1051-1059. Zhou, M., Xia, L., Engel, K., Wang, J.(2007) Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family. J Biol Chem, 282, 3188-3195. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55437 | - |
dc.description.abstract | 血腦屏障(Blood-brain barrier)是體循環血液與中樞神經系統的分界,阻止許多物質進入中樞神經系統,包括藥物與毒物。腦微血管內皮細胞組成有如表皮細胞般的細胞間緊密連結(Tight junction; TJ) 因此造就了屏障的特性,使大部分物質進出腦部需要轉運蛋白的協助而無法經由細胞間隙進入。許多溶質轉運蛋白(Solute carrier; SLC)表達於腦微血管內皮細胞上,包括有機陽離子轉運蛋白(organic cation transporters; OCTs; SLC22A1-2)及漿膜單胺轉運蛋白(plasma membrane monoamine transporter; PMAT; SLC29A4)。
本實驗將腦部的微血管分別從Swiss小鼠、C57BL/6 (B6)小鼠和Wistar大鼠分離,偵測其上Octs及Pmat的表現量。並偵測在以脂多醣 (lipopolysacchride; LPS)處理前及處理後轉運蛋白表達量的變化。我們以免疫螢光染色(immunofluorescence) 和反轉錄即時定量聚合酶連鎖反應(reverse transcription-quantitative polymerase chain reaction; RT-qPCR) 來偵測其上的蛋白及mRNA的表達。而我們也進一步以體外模型探討LPS對Octs及Pmat的調控是否受星狀細胞(astrocyte)及周邊細胞(pericyte)所影響。另外,我們也利用過度表達Octs及Pmat的MDCK細胞株來探討內生性神經毒物1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP),N-methyl-(R)-salsolinol(N-methyl-(R)SAL)及 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-benzyl-TIQ)的動力學性質。 研究結果顯示,Oct1及Oct2的mRNA相較於腦皮質,集中表現於B6小鼠的腦微血管。Oct1、Oct2及Pmat的蛋白則與內皮細胞的標記蛋白(markers),如CD31(cluster of differentiation 31)、第四型膠原蛋白(Collagen IV)共位表現(co-localized)。體內試驗結果顯示,Oct1、Oct2及Pmat的蛋白表現量在給予LPS後,短期與長期分別是上升與下降。體外試驗結果顯示,在給予急性LPS刺激下,星狀細胞對於轉運蛋白表達量的調控扮演重要的角色。最後,動力學實驗方面發現人類OCT1可以運輸1-benzyl-TIQ 及N-methyl-(R)SAL;人類PMAT 可以運送 1-benzyl-TIQ及MPTP。 總而言之,Oct1-2及Pmat表達於B6小鼠及Wistar 大鼠的腦微血管,但並未表達於Swiss小鼠的腦微血管。急性與長期LPS的刺激對Oct1、Oct2及Pmat的表達量,有相反的調控。根據結果可以推測,這些轉運蛋白表達量的改變會改變血腦屏障對神經毒性物質N-methyl-(R)SAL、 1-benzyl-TIQ 及MPTP的運送,進而影響所造成之毒性。 | zh_TW |
dc.description.abstract | The blood–brain barrier (BBB) is the interface separating the circulation blood from the brain extracelluar fluid in central nervous system (CNS). The BBB prevents brain uptake of many substrates, including pharmaceuticals and toxins. This property arises from the epithelial-like tight junctions formed by the brain microvascular endothelial cells (BMECs). Several solute carrier (SLC) families are expressed on BMECs, including SLC22 and SLC29, mediating the transportation of a variety of substances.
In this study, the expression of organic cation transporters (Octs; slc22A1-2) and plasma membrane monoamine transporter (Pmat; slc29a4) were measured in brain microvessels (BMV) isolated from Swiss mice, C57BL/6 (B6) mice and Wistar rats before and after lipopolysaccharide(LPS) treatment. Immunofluorescence and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to measure the expression of mRNA and protein, respectively. The effects of LPS on the regulation of Oct1, Oct2 and Pmat were further investigated in BMECs with or without co-culture with astrocyte and pericyte. Also, the kinetics properties of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP),N-methyl-(R)-salsolinol(N-methyl-(R)SAL) and 1-benzyl-1,2,3,4-tetrahydroisoquinoline(1-benzyl-TIQ), were measured in MDCK cells expressing human OCTs or PMAT. The results showed that the mRNA of Oct1 and Oct2, but not Oct3, were enriched in BMV of B6 mice (compare to cerebral cortex). Oct1, Oct2 and Pmat proteins were co-localized with endothelial markers (CD31, collagen IV, and p-glycoprotein). Protein levels of Oct1, Oct2 and Pmat protein levels were increased and reduced, respectively, upon acute and long-term LPS treatment. Result of in vitro BMECs co-culturing system showed that astrocyte play a role on the up-regulation of Octs and Pmat after acute LPS treatment. Finally, the kinetic study showed that human OCT1 can transport both 1-benzyl-TIQ and N-methyl-(R)SAL. Human PMAT can transport 1-benzyl-TIQ and MPTP. In conclusion, Oct1-2 and Pmat were expressed in BMV of C57BL/6 (B6) mice and Wistar rats, but not of Swiss mice. Acute and long-term LPS treatment regulated Oct1-2 and Pmat expression, but in a different manner. These data suggests that the change in the expression of Octs and Pmat at BMV may change BBB transport of N-methyl-(R)SAL, 1-benzyl-TIQ and MPTP. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T04:02:26Z (GMT). No. of bitstreams: 1 ntu-103-R01423008-1.pdf: 8301406 bytes, checksum: ecdce6258b0c9148bcc069261b6808c2 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Abstract i
摘要 iii 目錄 v 第一章 文獻回顧 1 1.1. 血腦屏障 1 1.2. 有機陽離子轉運蛋白 2 1.3. 漿膜單胺轉運蛋白之表達 3 1.4. 發炎反應對於轉運蛋白的調控 4 1.5. 巴金森氏症 5 1.6. 神經毒性物質與其在腦內的分布 6 1.7. TIQ與細胞膜轉運蛋白 8 第二章 研究目的 24 第三章 實驗方法 25 3.1.實驗材料 25 3.2. 實驗步驟 32 3.2.1. RNA樣品之抽取 32 3.2.1.1 組織樣品 32 3.2.1.2. 細胞樣品 32 3.2.1.3.品質控制 32 3.2.2. 反轉錄及定量聚合酶鏈鎖反應 33 3.2.2.1. 反轉錄反應 33 3.2.2.2. 定量即時聚合酶鏈鎖反應 33 3.2.2.3. 品質控制 34 3.2.3. 分離小鼠腦部微血管 34 3.2.4. 大鼠初代細胞分離與培養 35 3.2.4.1. 大鼠之初代腦微血管內皮細胞之分離及培養 35 3.2.4.2. 大鼠之初代腦周邊細胞之分離及培養 37 3.2.4.3. 大鼠之初代腦星狀細胞之分離及培養 37 3.2.4.4. 連續梯度Percoll之製備 38 3.2.5. 免疫細胞化學染色 38 3.2.6. 流式細胞儀 39 3.2.7. 初代細胞共同培養模型 40 3.2.8. hOCT1/hENT4基因轉殖 40 3.2.9. 細胞膜蛋白萃取 41 3.2.10. 蛋白質濃度測定 42 3.2.10.1. 細胞溶解物之蛋白濃度測定 42 3.2.10.2. 細胞膜蛋白萃取物與腦微血管蛋白萃取物之蛋白質濃度測定 42 3.2.11. 西方墨點法 43 3.2.12. MDCK-hOCT1/ MDCK-hPMAT system之確認 43 3.2.12.1. 時間相依性研究 44 3.2.12.2. 濃度相依性研究 44 3.2.13. N-methyl-(R)SAL與1-benzyl-TIQ抑制3H-MPP+在MDCK-hOCT1攝取量之研究 45 3.2.14. N-methyl-(R)SAL與1-benzyl-TIQ 在MDCK-hOCT1之動力學研究 46 3.2.14.1. 時間相依性研究 46 3.2.14.2. 濃度相依性研究 46 3.2.14.3. 超高效液態層析串聯質譜儀定量分析 47 3.2.15. MPTP 在MDCK-hPMAT之動力學研究 47 3.2.15.1. 時間相依性研究 47 3.2.15.2. 濃度相依性研究 48 3.2.16. 數據分析 48 第四章 實驗結果 55 4.1. 有機陽離子轉運蛋白與漿膜單胺轉運蛋白在腦微血管與大腦皮質之表達 55 4.1.1. 腦微血管及腦皮質上轉運蛋白之mRNA表達量 55 4.1.2. 腦微血管上之轉運蛋白之蛋白表達 55 4.2. 脂多醣引起發炎對於腦部有機陽離子轉運蛋白表現量之影響 56 4.3. 以體外血腦屏障模型探討發炎狀態對轉運蛋白之調控 56 4.3.1. 初代細胞分離 57 4.3.2 體外血腦屏障模型探討發炎對轉運蛋白之影響 57 4.4. MDCK-hOCT1 及MDCK-hPMAT之建立 59 4.4.1. MDCK-hOCT1 59 4.4.2. MDCK-hPMAT 60 4.5. N-methyl-(R)SAL、1-benzyl-TIQ與MPP+在MDCK-hOCT1上作用關係之探討 61 4.6. N-methyl-(R)SAL與1-benzyl-TIQ在MDCK-hOCT1的動力學試驗 62 4.6.1. N-methyl-(R)SAL與1-benzyl-TIQ在MDCK-hOCT1的攝取量之時間相依性研究 62 4.6.2. N-methyl-(R)SAL與1-benzyl-TIQ在MDCK-hOCT1的攝取量之濃度相依性研究 62 4.7. MPTP在MDCK-hPMAT細胞上作用關係之探討 63 4.7.1. MPTP在MDCK-hPMAT的攝取量之時間相依性研究 63 4.7.2. MPTP在MDCK-hPMAT的攝取量之濃度相依性研究 63 第五章 討論 76 5.1. 不同品系與物種間血腦屏障上轉運蛋白之表達 76 5.2. 發炎狀態與轉運蛋白之關係探討 76 5.3. 星狀細胞與周邊細胞在發狀態下調控轉運蛋白表達之角色 77 5.4. 巴金森氏症、發炎狀態與轉運蛋白之關聯性 78 5.5. 神經毒素與轉運蛋白之作用關係 80 5.6. 星狀細胞與神經毒性物質 81 第六章 結論 83 第七章 參考文獻 84 第八 附錄 92 | |
dc.language.iso | zh-TW | |
dc.title | 探討脂多醣影響血腦屏障上轉運蛋白表現之機制及轉運蛋白與神經毒性物質之作用關係 | zh_TW |
dc.title | LPS-mediated regulation of membrane transporters at the blood-brain barrier and the interaction between transporters and neurotoxins | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳儀莊(Yi-juang Chern),孔繁路(Fan-Lu Kung) | |
dc.subject.keyword | 脂多醣,有機陽離子轉運蛋白,漿膜單胺轉運蛋白,血腦屏障,神經毒物, | zh_TW |
dc.subject.keyword | lipopolysaccharide,organic cation transporter,plasma membrane transporter,blood-brain barrier,neurotoxin, | en |
dc.relation.page | 101 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-10-17 | |
dc.contributor.author-college | 藥學專業學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
Appears in Collections: | 藥學系 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-103-1.pdf Restricted Access | 8.11 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.